Akademik Veri Yönetim Sistemi
13. International drug Chemistry Conference, Antalya, Türkiye, 6 - 09 Şubat 2025, ss.24, (Tam Metin Bildiri)
Ribociclib is a selective Cyclin-Dependent Kinase (CDK) 4/6 inhibitor used in cancer treatment. This compound is specifically employed in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Ribociclib inhibits the activity of CDK4 and CDK6, which regulate progression through the G1 phase of the cell cycle, thereby halting tumor cell proliferation. Clinical studies have demonstrated that ribociclib significantly improves progression-free survival rates 1. Moreover, its targeted mechanism of action ensures a lower toxicity profile compared to traditional chemotherapy2. The pharmacokinetic properties of ribociclib, including its oral bioavailability and minimal side effects, make it a promising agent in the treatment of advanced-stage cancer3,4. WKthKn the scope of thKs study, Kt was aKmed to produce rKbocKclKb compound on a large scale through a dKfferent and novel synthesKs.